D-0120-2018 Class I Terminated
FDA drug recall D-0120-2018 was initiated by Amneal Pharmaceuticals Of New York, LLC on Aug 3, 2017 and is designated Class I. Reason for recall: Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing. The recall status is terminated (terminated Sep 7, 2022). Affected quantity: 136376 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 27, 2017
- Initiation Date
- Aug 3, 2017
- Termination Date
- Sep 7, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 136376 bottles
Product description
Lorazepam Oral Concentrate, USP, 2 mg/mL, 30 mL bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Branchburg, NJ 08876. Distributed by: Amneal Pharmaceuticals, Glasgow, KY 42141. NDC 65162-687-84
Reason for recall
Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing.
Distribution pattern
Nationwide
Code information
Lot 06876016A, 06876017A, 06876018A, Exp 08/2018; 06876019A, 06876020A, 06876021A, 06876022A, Exp 09/2018; 06876023A, Exp 11/2018; 06876024A, 06876025A, Exp 12/2018; 06877001A, 06877002A, Exp 02/2019; 06877003A, Exp 03/2019.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0120-2018
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026